Literature DB >> 34268082

Application value of conventional ultrasound combined with shear wave elastography in diagnosing triple negative breast cancer.

Changrui Sheng1, Shanshan Gao1, Liming Yan1, Hua Yin1, Jingjing Hu1, Zhiying Ye1, Xiuzhi Wei1.   

Abstract

BACKGROUND: At present, most ultrasound (US) studies on triple negative breast cancer (TNBC) are limited to conventional US features, so it is necessary to develop new joint diagnostic methods. The study aims to explore the values of conventional US and shear wave elastography (SWE) in differential diagnoses of TNBC and non-TNBC.
METHODS: A total of 120 breast cancer (BC) patients involving 120 lesions that were pathologically verified were retrospectively analyzed in this study. All participants had received both conventional US and SWE before surgery. Meanwhile, the participants were divided into a TNBC group or a non-TNBC group according to their immunohistochemical (IHC) results. The differences between the conventional US features (including lesion shape, growth location, margin, boundary, internal echo, micro-calcification, posterior echo, and internal blood supply) and the SWE image features [including mean lesion hardness (Emean), maximum (Emax), minimum (Emin), standard deviation (SD), and ratio to normal gland (Eratio)] of 2 groups were compared. The receiver operating characteristic (ROC) curve of the diagnosed lesion was calculated by the area under the curve (AUC).
RESULTS: According to the findings of conventional US, the TNBC group mostly manifested as a micro-lobulated margin, with a clear boundary and no internal micro-calcification; the non-TNBC group mainly manifested as marginal angulation or burr, and hyper-echo halo in the boundary, accompanied with internal micro-calcification, and the difference was statistically significant (P<0.05); the internal thrombolysis in myocardial infarction (TIMI) and resistance index between the TNBC group and non-TNBC group were similar, and the differences were not statistically significant (P>0.05). The findings of SWE were as follows: differences in Emax, Emean, and Eratio values between 2 groups were statistically significant (P<0.05); and the areas under the ROC curve (AUC) of these three in diagnosing the lesions were 0.811, 0.781 and 0.770, respectively.
CONCLUSIONS: Conventional US combined with SWE can comprehensively analyze the morphological, blood supply, and hardness features of breast lesions, and provide more reliable information for the differential diagnosis between TNBC and non-TNBC. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Ultrasonography; shear wave elastography (SWE); triple negative breast cancer (TNBC)

Year:  2021        PMID: 34268082      PMCID: PMC8258874          DOI: 10.21037/gs-21-320

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  31 in total

1.  Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Authors:  Francesca Riva; Francois-Clement Bidard; Alexandre Houy; Adrien Saliou; Jordan Madic; Aurore Rampanou; Caroline Hego; Maud Milder; Paul Cottu; Marie-Paule Sablin; Anne Vincent-Salomon; Olivier Lantz; Marc-Henri Stern; Charlotte Proudhon; Jean-Yves Pierga
Journal:  Clin Chem       Date:  2017-01-10       Impact factor: 8.327

2.  Use of shear wave elastography to differentiate benign and malignant breast lesions.

Authors:  Deniz Çebi Olgun; Bora Korkmazer; Fahrettin Kılıç; Atilla Süleyman Dikici; Mehmet Velidedeoğlu; Fatih Aydoğan; Fatih Kantarcı; Mehmet Halit Yılmaz
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

3.  Shear wave elastography of tumour growth in a human breast cancer model with pathological correlation.

Authors:  Foucauld Chamming's; H Latorre-Ossa; M A Le Frère-Belda; V Fitoussi; T Quibel; F Assayag; E Marangoni; G Autret; D Balvay; L Pidial; J L Gennisson; M Tanter; C A Cuenod; O Clément; L S Fournier
Journal:  Eur Radiol       Date:  2013-04-04       Impact factor: 5.315

4.  Elastographic features of triple negative breast cancers.

Authors:  Martina Džoić Dominković; Gordana Ivanac; Tomislav Kelava; Boris Brkljačić
Journal:  Eur Radiol       Date:  2015-08-01       Impact factor: 5.315

5.  Systematic Review and Meta-analysis of the Malignant Ultrasound Features of Triple-Negative Breast Cancer.

Authors:  Lu Tian; Longlun Wang; Yong Qin; Jinhua Cai
Journal:  J Ultrasound Med       Date:  2020-04-27       Impact factor: 2.153

Review 6.  Therapeutic strategies for triple-negative breast cancer.

Authors:  Antoinette R Tan; Sandra M Swain
Journal:  Cancer J       Date:  2008 Nov-Dec       Impact factor: 3.360

7.  Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway.

Authors:  Weilong Zhong; Shuang Chen; Yuan Qin; Heng Zhang; Hongzhi Wang; Jing Meng; Longcong Huai; Qiang Zhang; Tingting Yin; Yueyang Lei; Jingxia Han; Lingfei He; Bo Sun; Huijuan Liu; Yanrong Liu; Honggang Zhou; Tao Sun; Cheng Yang
Journal:  Oncotarget       Date:  2017-08-24

8.  ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma.

Authors:  Xiaonan Xi; Ning Liu; Qianqian Wang; Yahui Chu; Zheng Yin; Yahui Ding; Yaxin Lu
Journal:  Cell Death Dis       Date:  2019-10-07       Impact factor: 8.469

Review 9.  Recent advances in triple negative breast cancer: the immunotherapy era.

Authors:  Antonio Marra; Giulia Viale; Giuseppe Curigliano
Journal:  BMC Med       Date:  2019-05-09       Impact factor: 8.775

10.  TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.

Authors:  Utpal K Mukhopadhyay; Chetan C Oturkar; Christina Adams; Nadi Wickramasekera; Sanjay Bansal; Rajesh Medisetty; Austin Miller; Wendy M Swetzig; Laxmi Silwal-Pandit; Anne-Lise Børresen-Dale; Chad J Creighton; Jun Hyoung Park; Santhi D Konduri; Alka Mukhopadhyay; Alexander Caradori; Angela Omilian; Wiam Bshara; Benny Abraham Kaipparettu; Gokul M Das
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 11.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.